New York, USA, July 22, 2024 (GLOBE NEWSWIRE) -- DelveInsight’s report includes a comprehensive understanding of current treatment practices, emerging cell and gene therapy in Parkinson's disease, market share of individual therapies, and current and forecasted cell and gene therapy in Parkinson's disease market size from 2020 to 2034, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan]. Discover which therapies are expected to grab the cell and gene therapy in Parkinson's disease market share @ Parkinson’s disease is a progressive condition resulting from the degeneration of nerve cells in the brain region known as the substantia nigra, primarily impacting movement. Motor symptoms of Parkinson’s include tremors, slowness of movement (bradykinesia), stiffness, and postural instability.
Non-motor symptoms can encompass cognitive impairment, mood disorders, sleep problems, and autonomic dysfunction. If left unmanaged, these symptoms can significantly reduce a patient's quality of life. Additionally, the progressive nature of the disease imposes a considerable burden on caregivers.
The exact cause of Parkinson’s disease remains unknown, but it is believed to result from a combination of environmental risk factors and genetic predisposition. Men are slightly more prone to the disease than women, and it usually affects individuals over 60, though early-onset cases do occur. The main pathology involves the dege.